Kintegral Advisory’s West Pharmaceutical WST Stock Holding History

Kintegral Advisory’s Portfolio WST Stock Details WST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.42M	Buy	3,834 +21	+0.6%	+$7.41K	0.11%	150
2026 Q2	$1.37M	Hold	3,813	–	–	0.11%	157
2026 Q1	$956K	Sell	3,813 -169	-4%	-$42K	0.09%	172
2025 Q4	$1.1M	Sell	3,982 -109	-3%	-$29.8K	0.09%	165
2025 Q3	$1.07M	Sell	4,091 -18	-0.4%	-$4.38K	0.09%	173
2025 Q2	$899K	Sell	4,109 -6	-0.1%	-$1.28K	0.08%	183
2025 Q1	$921K	Sell	4,115 -13	-0.3%	-$3.58K	0.09%	183
2024 Q4	$1.35M	Sell	4,128 -192	-4%	-$60.4K	0.13%	155
2024 Q3	$1.3M	Sell	4,320 -57	-1%	-$17.5K	0.12%	161
2024 Q2	$1.44M	Sell	4,377 -6,736	-61%	-$2.38M	0.14%	149
2024 Q1	$4.4M	Sell	11,113 -35	-0.3%	-$12.9K	0.44%	62
2023 Q4	$3.93M	Sell	11,148 -71	-0.6%	-$25.1K	0.43%	61
2023 Q3	$4.21M	Sell	11,219 -7	-0.1%	-$2.71K	0.52%	55
2023 Q2	$4.29M	Hold	11,226	–	–	0.51%	55
2023 Q1	$3.89M	Sell	11,226 -603	-5%	-$176K	0.5%	59
2022 Q4	$2.78M	Buy	+11,829	New	+$2.8M	0.37%	91

Other funds holding WST

Border to Coast Pensions Partnership Leeds, United Kingdom $7.27B AUM 24.98% 1-Year Est. Return

Birch Hill Investment Advisors Boston, Massachusetts $2.43B AUM 15.45% 1-Year Est. Return

AMI Asset Management Los Angeles, California $1.74B AUM 24.77% 1-Year Est. Return

Seilern Investment Management London, United Kingdom $771M AUM 2.59% 1-Year Est. Return

Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

North Growth Management Vancouver, British Columbia, Canada $743M AUM 74.29% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

Nisa Investment Advisors St. Louis, Missouri $34.7B AUM 25.93% 1-Year Est. Return

MCG

McCollum Christoferson Group Amherst, New York $343M AUM 13.42% 1-Year Est. Return

Kintegral Advisory's WST Position: Q3 2026 in Review

Kintegral Advisory increased its West Pharmaceutical (WST) stake by 0.55% in Q3 2026, buying an estimated $7.41K and bringing the position to 3,834 shares worth $1.42M. The position accounts for 0.11% of the portfolio, ranked #150.

Kintegral Advisory first reported a position in WST in Q4 2022 and has held it in 16 quarters since. The position peaked at $4.4M in Q1 2024. 141 funds tracked by Wall St. Rank hold WST as of Q3 2026.

Kintegral Advisory held 3,834 shares of West Pharmaceutical worth $1.42M as of Q3 2026.
Kintegral Advisory bought 21 West Pharmaceutical shares in Q3 2026, an estimated $7.41K.
West Pharmaceutical made up 0.11% of Kintegral Advisory's portfolio in Q3 2026, its #150 holding.
Kintegral Advisory first reported a position in West Pharmaceutical in Q4 2022 and has held it in 16 quarters since.
Kintegral Advisory's West Pharmaceutical position peaked at $4.4M in Q1 2024.
141 funds tracked by Wall St. Rank held West Pharmaceutical as of Q3 2026.

Based on Kintegral Advisory's 13F filing for Q3 2026, filed 16 Oct 2026.